Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis
Eliano Pio Navarese, Michalina Kolodziejczak, Volker Schulze, Paul A Gurbel, Udaya Tantry, Yingfeng Lin, Maximilian Brockmeyer, David E Kandzari, Julia M Kubica, Ralph B D'Agostino Sr, Jacek Kubica, Massimo Volpe, Stefan Agewall, Dean J Kereiakes, Malte Kelm, Eliano Pio Navarese, Michalina Kolodziejczak, Volker Schulze, Paul A Gurbel, Udaya Tantry, Yingfeng Lin, Maximilian Brockmeyer, David E Kandzari, Julia M Kubica, Ralph B D'Agostino Sr, Jacek Kubica, Massimo Volpe, Stefan Agewall, Dean J Kereiakes, Malte Kelm
Abstract
Background: Guidelines recommend statins as first-line therapy for dyslipidemia. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new lipid-lowering approach.
Purpose: To assess the efficacy and safety of PCSK9 antibodies in adults with hypercholesterolemia.
Data sources: MEDLINE, PubMed Central, and Google Scholar; conference proceedings; and the ClinicalTrials.gov registry through 4 April 2015.
Study selection: Phase 2 or 3 randomized, controlled trials (RCTs) comparing treatment using PCSK9 antibodies with no anti-PCSK9 therapy in adults with hypercholesterolemia.
Data extraction: Two investigators independently extracted data on study characteristics and lipid and clinical outcomes, and rated risk of bias of trials. Prespecified primary end points were all-cause and cardiovascular mortality.
Data synthesis: Twenty-four RCTs comprising 10 159 patients were included. Compared with no antibody, treatment with PCSK9 antibodies led to marked reductions in low-density lipoprotein cholesterol levels (mean difference, -47.49% [95% CI, -69.64% to -25.35%]; P < 0.001] and other atherogenic lipid fractions, and it reduced all-cause mortality (odds ratio [OR], 0.45 [CI, 0.23 to 0.86]; P = 0.015; heterogeneity P = 0.63; I2 = 0%) and cardiovascular mortality (OR, 0.50 [CI, 0.23 to 1.10]; P = 0.084; heterogeneity P = 0.78; I2 = 0%). The rate of myocardial infarction was significantly reduced with use of PCSK9 antibodies (OR, 0.49 [CI, 0.26 to 0.93]; P = 0.030; heterogeneity P = 0.45; I2 = 0%), and increases in the serum creatine kinase level were reduced (OR, 0.72 [CI, 0.54 to 0.96]; P = 0.026; heterogeneity P = 0.65; I2 = 0%). Serious adverse events did not increase with administration of PCSK9 antibodies.
Limitation: Results were derived from study-level data rather than patient-level data, and clinical outcome data are rare.
Conclusion: PCSK9 antibodies seem to be safe and effective for adults with dyslipidemia.
Primary funding source: CRC 1116 Masterswitches in Myocardial Ischemia, German Research Council DFG.
Source: PubMed